Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 6/2013

01-12-2013 | Original Article

Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

Authors: P. A. Laires, F. Exposto, R. Mesquita, A. P. Martins, L. Cunha-Miranda, J. E. Fonseca

Published in: The European Journal of Health Economics | Issue 6/2013

Login to get access

Abstract

Background

Despite the widespread availability of biologics across Europe, rheumatoid arthritis (RA) patients’ access to these drugs differs significantly among countries.

Objectives

To compare the proportion of RA patients treated with biologics across Europe and investigate the factors that most influence it, with focus on the Portuguese case, reportedly with low access rates to biologics.

Methods

The biologics’ market was characterized for 15 selected European countries. Variables potentially influencing patients’ access to biologics (PAB) in RA were also collected, including demographic, disease, economic, funding and biologics’ market-related data. A multivariable regression model identified the factors that best explain PAB. Based on these determinants, a cluster analysis was performed to group the countries with most similar behaviour regarding PAB allowing the evaluation of Portugal’s relative position among these countries.

Results

The regression model (R 2 = 0.953) indicated that PAB in selected countries is explained mostly by its gross domestic product (GDP) per capita, the usage of methotrexate (MTX) and the biologics’ distribution channel. Current MTX usage in Portugal shows similarity with practice from UK, France, Germany or Spain 5 years before, explaining why PAB in Portugal stood at 7 % in 2010, 12 percentage points below the average of selected countries.

Conclusions

Variations in RA PAB were found across selected countries with Portugal showing the lowest proportion. GDP per capita, biologics distribution channel and consumption of MTX appear to be the best explanatory factors for these fluctuations in European countries.
Literature
1.
Chen, Y.F., Jobanputra, P., Barton, P., et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 3–4 (2006)
2.
Kvien, T.K.: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22, 1–12 (2004)PubMedCrossRef
3.
Matos, A.A., Branco, J.C., Canas Silva, J., Viana Queiroz, M., Pádua, F.: Inquérito epidemiológico de doenças reumáticas numa amostra da população portuguesa (resultados preliminares). Acta Reumatol. Port. 16(1), 98 (1991)
4.
National Institute for Health and Clinical Excellence: Rheumatoid arthritis—National clinical guideline for management and treatment in adults. NICE, London (2009)
5.
6.
Smolen, J.S., Landewé, R., Breedveld, F.C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964–975 (2010). doi:10.​1136/​ard.​2009.​126532 PubMedCrossRef
7.
8.
9.
Miltenburger, C., Gunther, O., Justo, N., et al.: A survey of barriers to treatment access in rheumatoid arthritis in France, Germany, Italy, Spain and the UK (2009). Accessed December 2011
10.
Emery, P., Van Vollenhoven, R., Ostergaard, M., et al.: Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68(4), 456–459 (2009). doi:10.​1136/​ard.​2008.​100362 PubMedCrossRef
11.
Cruz, M., Fonseca, J.E., Branco, J.C.: Artrite reumatóide: paradigma das doenças reumáticas crónicas. Tecnologia Médica 2, 2–11 (2002)
12.
Cruz, M., Fonseca, J.E., Branco, J.C.: Três anos de administração de etanercept e infliximab a doentes com artrite reumatóide refractária—avaliação clínica e radiográfica e segurança. Acta Reumatol. Port. 29, 21–32 (2004)
13.
Barcelos, A., Salvador, M.J., da Silva, J.A., et al.: Indução de auto anticorpos durante tratamento prolongado com infliximab em doentes com artrite reumatóide. Acta Reumatol. Port. 29, 161–167 (2004)
14.
Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia: Análise de 376 doentes com Artrite Reumatóide submetidos a terapêutica biológica registados na base de dados de agentes biológicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol. Port. 30, 63–71 (2005)
15.
Canhão, H., Faustino, A., Martins, F., et al.: Reuma.pt—the rheumatic diseases portuguese register. Acta Reumatol. Port. 36(1), 45–56 (2011)PubMed
16.
17.
18.
19.
20.
21.
Observatório Do Medicamento e Produtos de Saúde: Consumo de Medicamentos em meio hospitalar. In. INFARMED (2010)
22.
MIDAS Database. IMS Health. Accessed January 2011
23.
Orlewska, E., Ancuta, I., Anic, B., et al.: Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med. Sci. Monit. 17(4), SR1–SR13 (2011)PubMedCrossRef
24.
Rousseeuw, P.J.: Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. Computational and applied mathematics. J. Comput. Appl. Math. (1987). doi:10.​1016/​0377-0427(87)90125-7
25.
Associação Nacional dos Doentes com Artrite Reumatóide: Impacto dos medicamentos biológicos na qualidade de vida dos doentes. Paper presented at the Plataforma Mais Saúde, INFARMED, Portugal, 22 Nov 2011
26.
Cunha-Miranda, L., Santos, H., Ferreira, J., et al.: Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden. Acta Reumatol. Port. (37), 134–142 (2012)
27.
28.
Ramiro, S., Canhão, H., Branco, J.C.: EpiReumaPt protocol—Portuguese epidemiologic study of the rheumatic diseases. Acta Reumatol. Port. 35(3), 384–390 (2010)PubMed
29.
Drosos, A.A., Lanchbury, J.S., Panayi, G.S., et al.: Rheumatoid arthritis in greek and british patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35(7), 745–748 (1992). doi:10.​1002/​art.​1780350705
30.
Salvarani, C., Macchioni, P.L., Mantovani, W., et al.: HLA-DRB1 alleles associated with rheumatoid arthritis in northern Italy: correlation with disease severity. Br. J. Rheumatol. 37, 165–169 (1998)PubMedCrossRef
31.
Ronda, E., Ruiz, M.T., Pascual, E., et al.: Differences between Spanish and British patients in the severity of rheumatoid arthritis: comment on the article by Drosos et al. Arthritis Rheum. 37(1), 147–148 (1994). doi:10.​1002/​art.​1780370125 PubMedCrossRef
32.
Benazet, J.F., Reviron, D., Mercier, D., et al.: HLADRB1 alleles associated with rheumatoid arthritis in southern France: absence of extraarticular disease despite expression of the shared epitope. J. Rheumatol. 22, 607–610 (1995)PubMed
Metadata
Title
Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
Authors
P. A. Laires
F. Exposto
R. Mesquita
A. P. Martins
L. Cunha-Miranda
J. E. Fonseca
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 6/2013
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-012-0432-5

Other articles of this Issue 6/2013

The European Journal of Health Economics 6/2013 Go to the issue

Editorial

Channeling health economics research initiatives to improve decision-making processes in the EU

Original Paper

Quantifying short run cost-effectiveness during a gradual implementation process

Original Paper

How efficient are Greek hospitals? A case study using a double bootstrap DEA approach

Original Paper

The impact of generic reference pricing in Italy, a decade on

Original Paper

Treatment costs of attention deficit hyperactivity disorder in Germany

Original Paper

Maximal endurable time states and the standard gamble: more preference reversals